Nanogenerator

Wireless biosensors that monitor pathogens in water and measure blood pressure or cancer biomarkers in the body are shrinking to nanometer dimensions. To operate them, researchers are looking for equally small power sources. Nanowires that convert mechanical energy into electricity are a promising technology.

Now researchers at the University of Illinois at Urbana-Champaign (UIUC) have taken the first step toward building a nanogenerator out of barium titanate. So far, efforts to make nanogenerators have focused on zinc-oxide nanowires. But barium titanate could lead to better generators because it shows a stronger piezoelectric effect, says mechanical-science and engineering professor Min-Feng Yu, who is leading the research at UIUC. Lab experiments show that a barium-titanate nanowire can generate 16 times as much electricity as a zinc-oxide nanowire from the same amount of mechanical vibrations, he says.

Nanogenerators could lead to many advances: biomedical sensors powered by blood flow or muscle contractions, tiny gas sensors that run on wind or acoustic waves, pathogen monitors powered by water flow, and portable electronics that are hooked up to nanowires in shoes. "The nanogenerator idea has become more and more convincing, " says Yi Cui, materials-science and engineering professor at Stanford University. "It's an idea that might work."

In 2006, a team of researchers led by Zhong Lin Wang of the Georgia Institute of Technology first showed that zinc-oxide nanowires could harvest mechanical energy to generate electricity. Wang's group has since made a lot of progress, most recently demonstrating a zinc-oxide nanowire array that outputs direct current in response to ultrasonic vibrations. (See "Nanogenerator Fueled by Vibrations.")

The UIUC team is the first to use barium titanate. In an online Nano Letters paper, Yu and his colleagues show that applying vibrations to a single barium-titanate nanowire leads to a small energy output. In their experiment, the researchers bridge a nanowire across a gap on a substrate, keeping one end stationary and moving the other end. The output energy is extremely small--about 0.3 attojoules--but for the same setup, a zinc-oxide nanowire gives 16 times lesssmaller energy output, Yu says.

Xudong Wang, a researcher in Zhong Lin Wang's (no relation) group and a 2007 TR35 winner, is happy to see progress on using materials other than zinc oxide to make nanogenerators. He says that the results look promising. The biggest advantage with using barium titanate, he feels, is that "it is possible to generate higher voltages than zinc oxide. This is very important for a power source."

But zinc oxide has its own advantages. It is nontoxic to biological systems, so it might be better suited than barium titanate for implantable devices. Also, it is easier to control zinc-oxide growth in order to fabricate nanowire arrays. "To make an applicable device, you need to have many nanowires with the same orientation in the same location," Xudong Wang says. That could be hard to achieve with barium titanate.

Yu acknowledges the difficulties with growing barium-titanate nanowires. His and his colleagues' work is preliminary at this point, he says, but it already shows the potential for making more-efficient, higher-output nanogenerators. As for Cui, he says that barium-titanate nanogenerators might be feasible, but he cautions that "in terms of making a working device, certainly there's still a way to go."

Experimental Drugs

Two new classes of experimental drugs shown to have powerful muscle-building capabilities--selective androgen receptor modulators (SARMs) and myostatin inhibitors--have been added to the World Anti-Doping Agency's (WADA) list of prohibited substances for 2008. Neither class of drugs is yet on the market. But the agency, an international, independent organization based in Lausanne, Switzerland, that coordinates anti-doping regulations across sports, is gearing up for future abuse by limiting use among athletes and by developing new detection methods. "We now have convincing data on those drugs and what they can do," says Olivier Rabin, science director at WADA. "We have a duty to act as early as we can when drugs have the potential to be doping agents."

Unlike with testosterone and other anabolic steroids, the action of SARMs and myostatin inhibitors is restricted to muscle, likely limiting side effects. That's a very good thing for patients, but it also makes the drugs more attractive to those looking to bulk up. "I think there's a whole new horizon for anabolic therapies, and the potential for abuse will be exceedingly high," says William Evans, director of the Nutrition, Metabolism, and Exercise Laboratory at the University of Arkansas for Medical Sciences.

Compounds of both classes are currently in clinical trials for muscle wasting related to diseases such as cancer and muscular dystrophy. There have been no official reports of athletes using these drugs, but because there previously have been cases of athletes gaining access to compounds in clinical development, WADA officials say that they want to act early.

SARMs work similarly to testosterone but in a more targeted way. "They are effective by binding to the steroid receptor in only specific tissue, like muscle," says Evans, who is also a scientific advisor to GTx, a company developing the drugs. "They are not steroid drugs, but they produce the anabolic effect of the steroids." GTx, based in Memphis, TN, has shown in a clinical trial that one compound being developed for muscle wasting and bone loss can significantly boost lean muscle mass in older people.

Myostatin inhibitors work through a fundamentally different mechanism. They block myostatin, a naturally occurring protein in the body that stops growth of skeletal muscle. Cattle, sheep, dogs, and, in one confirmed case, a human with mutations in this gene are extremely muscular. (See "Mimicking the Massively Muscular.")

Scientists have developed antibodies to myostatin and other molecules that can boost lean muscle mass in animals by as much as 60 percent. It's not yet clear how well myostatin inhibitors will work in humans. Clinical studies of two myostatin inhibitors are now under way for muscular dystrophy and other muscle-wasting diseases.

WADA is developing detection methods for both SARMs and myostatin inhibitors, although the agency declined to say how far along those tests are. "In fairness to athletes who stay clean, we don't say when detection tools are available," says Rabin. "We say when we detect the first athletes using the drugs."

ther groups are more public about their progress. Acceleron, a company based in Cambridge, MA, that is developing a myostatin inhibitor, says that it has already developed a test for research purposes that is capable of detecting the drug in blood. And scientists at the Center for Preventive Doping Research, German Sport University Cologne, are working on a test for SARMs.

Fortunately, scientists say that detecting abuse of these two new classes of drugs is likely to be easier than detecting two doping agents that have plagued the sports world in recent years. Erythropoietin, which stimulates growth of red blood cells and is used to treat anemia patients, is processed quickly by the body, making it difficult to detect.Human growth hormone, which boosts cell growth, is a naturally occurring hormone. Tests must be able to discriminate between the natural hormone and the pharmaceutically derived version. "People who are trying to cheat like to use a steroid naturally present in the body, because it makes it much more difficult for labs to detect," says Don Catlin, founder of Anti-Doping Research, a nonprofit research institute based in Los Angeles.

Myostatin inhibitors present a particularly interesting case for WADA. In 2004, scientists published a paper describing an abnormally muscular German toddler who carried mutations in both copies of his myostatin gene. The boy's mother, who had been a professional athlete, was found to have one defective copy of the gene, raising questions about how to deal with athletes who have naturally occurring genetic mutations that give them benefits similar to those offered by performance-enhancing drugs. "We have ethicists thinking about those issues and guiding us in the future," says Rabin. "We need to maintain fair play for all competitors." The issue is likely to grow as advances in genomics allow scientists to uncover additional variants linked to muscle, or other factors related to athletic ability.